Drugs / Miyarisan-BM
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06548256 | Oct 2023 → Dec 2026 expected | Parkinson disease | Kaohsiung Medical University Chung-Ho Memorial Hospital | Recruiting | No outcome recorded |
| — | NCT03247101 | Feb 2016 → Dec 2017 | gallstones | Min-Sheng General Hospital | Unknown | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Miyarisan-BM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06548256 ↗ |
| Known as | Clostridium Butyricum Miyairi | “Miyarisan-BM (Clostridium Butyricum Miyairi)” NCT06548256 ↗1“Miyarisan-BM (Clostridium Butyricum Miyairi)” NCT03247101 ↗ |
| Modality | Other / unclassified | “probiotics” NCT06548256 ↗ |
| Route | Oral | “40mg po tid x 6months” NCT03247101 ↗ |